Exclusive: EU antitrust regulators to investigate $36 billion Mars bid for Kellanova, sources say

Mars' $36 billion acquisition of Kellanova is expected to face a full-scale EU antitrust investigation due to concerns about Mars' high market share in certain product categories within the European Union. The European Commission is acting as the antitrust watchdog and is concerned about the deal's impact on competition, potentially requiring Mars to divest assets. European retailers have voiced concerns about the power of large international suppliers and high concentration levels in sectors like breakfast cereals and confectionery.

Analysis

Mars' proposed $36 billion acquisition of Kellanova (K) is poised to undergo a full-scale EU antitrust investigation, signaling significant regulatory headwinds. The European Commission's concerns, as cited by sources, center on Mars' potentially dominant market share in specific product categories within certain EU member states. With the preliminary review concluding on June 25, Mars is reportedly unlikely to offer immediate remedies, increasing the probability of a protracted investigation and potential demands for asset divestitures to secure approval. This regulatory scrutiny emerges amidst a broader trend of consolidation within the U.S. packaged food industry, where companies are seeking scale to counteract shifting consumer preferences towards private label brands and navigate inflationary pressures. European retailers have also expressed apprehension regarding the combined entity's market power, particularly in concentrated segments like breakfast cereals and confectionery. The 'strongly negative' overall sentiment (-0.65) and specific negative sentiment for Kellanova (-0.5) underscore the material risks to the deal's completion in its current form and timeline.

Key Decisions for Investors

• Investors in Kellanova (K) should closely monitor developments from the EU antitrust investigation, as a full-scale probe introduces significant uncertainty, reflected in the negative sentiment, and potential downside risk to the $36 billion deal's timeline and terms.
• The likelihood of required asset divestitures by Mars warrants a re-evaluation of the deal's synergy potential and the ultimate value realization for Kellanova shareholders, potentially impacting the stock if the deal structure changes unfavorably.
• Given the 'uncertain' tone surrounding the regulatory process and the upcoming June 25th preliminary review deadline, investors should consider the heightened risk profile for Kellanova (K) and assess their exposure in light of potential delays or more stringent-than-anticipated remedies from the European Commission.